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ORIGINAL ARTICLE 
 
Targeting mycophenolate mofetil for graft-versus-ho st disease prophylaxis 
after allogeneic blood stem cell transplantation 
 
I Haentzschel1,3, J Freiberg-Richter1,3, U Platzbecker1, A Kiani1, J Schetelig1,  
T Illmer1, G Ehninger1, E Schleyer 2 and M Bornhauser1 
 
1Medizinische Klinik und Poliklinik I, University Hospital, Dresden, Germany and 
2Carl-von-Basedow Hospital, Merseburg, Germany 
 
 
As low trough levels of mycophenolic acid (MPA) hav e been measured in 
recipients of allo-SCTs, we performed a pilot study  targeting mycophenolate 
mofetil (MMF) doses according to the MPA area under  the concentration (AUC) 
levels. Twenty-nine patients were transplanted from  matched-sibling (n=7) and 
unrelated donors (n=22). Tacrolimus was given orall y from day –1 to achieve 
trough blood levels of 5–10 ng/ml. MMF was started on day 0 at 1500 mg 
intravenously b.i.d. AUC measurements of MPA by HPL C were scheduled on 
days 3, 7 and 11 after transplantation. The MMF dos e was modified to achieve 
an MPA AUC of 35 –60 lg/ml/h. With the respective adjustments, 66 and  75% 
surpassed the lower AUC target on days 7 and 11, re spectively. The cumulative 
incidence of grade III –IV acute GVHD was 28% (8/29). Eight out of 24 evalu able 
patients (33%) suffer from limited (n=3) or extensi ve (n=5) chronic GVHD. 
Overall, the results of this study suggest that tar geting of MPA exposure is 
feasible early after transplantation. A simplified MMF targeting strategy based 
on MPA C max or C2h levels seems to be warranted in future trials invo lving more 
patients at a later date in the outpatient setting.  
Bone Marrow Transplantation advance online publication, 24 March 2008; 
doi:10.1038/bmt.2008.85 
Keywords : mycophenolate mofetil; therapeutic drug monitoring; GVHD prophylaxis 
 
_______________________________________________________________________________________________________________________________________ 
 
Introduction 
 
Allogeneic hematopoietic SCT (HSCT) is performed with increasing frequency in the 
effort to cure patients with malignant hematological diseases. GVHD, one of the 
major risk factors after allogeneic transplantation, contributes to a transplant-related 
mortality of 15–30%.1 To reduce GVHD-related mortality, prophylactic and 
therapeutic immunosuppressive regimens including mycophenolate mofetil (MMF) 
have been investigated in clinical studies.2–5 One principal motivation of most 
investigators was to replace MTX by MMF to reduce the risk of mucosal, 
hematological and hepatic side effects associated with MTX. 
   Since 1995, Mycophenolate mofetil has been successfully used for the prevention 
of renal allograft rejection. Combined with CsA, MMF significantly reduced the rate of 
renal allograft rejection episodes during the first year.6 The bioavailability reported for 
MMF in healthy individuals is 94%. After absorption, MMF is rapidly hydrolyzed by 
esterases to the active compound mycophenolic acid (MPA). The hepatic 
glucuronidation of MPA by glucuronosyl transferase to MPA glucuronide (MPAG) is 
followed by an excretion of MPAG in the bile. MPAG is deconjugated by colonic 
bacteria back to MPA and reabsorbed to systemic circulation. Finally, over 48 h  
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post-dose, more than 71% of the administered dose undergoes renal elimination as 
MPAG. 
   Mycophenolic acid inhibits the inosine monophosphate dehydrogenase, which is 
the key enzyme in the pathway of de novo purine synthesis. In contrast to other cells, 
T and B lymphocytes rely on this pathway to synthesize guanosine-5'-triphosphate 
and dGTP, which are essential for DNA synthesis. In this way, the administration of 
MMF leads to selective inhibition of T- and B-cell proliferation. Because GVHD is 
predominantly mediated by donor T cells, MMF might have additive effects to 
standard immunosuppressive drugs for GVHD prophylaxis. Recent clinical studies 
support the hypothesis that higher cumulative doses and shorter dosing intervals 
seem to reduce the risk for acute GVHD at the expense of a moderate increase in 
unwanted side effects.7 
   In previous studies, we investigated MMF after oral and i.v. administration in 
combination with CsA as GVHD prophylaxis after allogeneic blood SCT from HLA-
compatible related and unrelated donors.3,8 No severe side effects and adverse 
events were observed. Compared to a control group receiving MTX and CsA, we saw 
no significant differences in the mucosal and intestinal toxicities and in the incidence 
of acute GVHD. However, measured trough plasma levels and the area under the 
concentration (AUC) vs time curve of MPA and MPAG after both routes of 
administration were much lower than measured in recipients of solid organ 
transplants or in healthy individuals.9,10 But still, the i.v. application of MMF at 
increasing dose levels was associated with an increase in AUC and a certain 
accumulation of MPA and MPAG over 3–4 weeks of therapy. A possible explanation 
of the decreased levels of MPA after oral administration could have been a reduced 
absorption rate caused by intestinal toxicity after high-dose conditioning. It is also 
conceivable that the enterohepatic recirculation of MPA was impaired by several 
factors. Given the metabolism and the elimination of the compound, a significant 
interpatient variability can be assumed. In addition, the clinical status as well as the 
organ function of recipients of allo-HSCT is prone to significant variation according to 
the intensity of conditioning, mucositis, infections and the occurrence of GVHD. 
   To account for most of these factors, we performed a pilot trial in which we aimed 
at infusing MMF at doses required to achieve a certain AUC target to individualize the 
exposition of patients toward the active metabolites of MMF. 
 
 
Patients and methods 
 
The patient’s and treatment characteristics are summarized in Table 1. Between July 
2004 and January 2006, 29 patients (17 male, 12 female) with a median age of 53 
(range, 21–69) years were included. Diagnosis included myelodysplastic 
syndrome/chronic myelomonocytic leukemia (n=8), de novo AML (n=11), 
nonHodgkin’s lymphoma (n=6), Hodgkin’s lymphoma (n=2) and multiple myeloma 
(n=2). Cytogenetic risk categories for all AML and myelodysplastic syndrome patients 
are provided in Table 1. Informed consent was obtained in all cases and was 
documented using forms approved by the Institutional Review Board. 
 
 
Conditioning therapy 
The preparative regimen included 30 mg/m2 fludarabine infused over 30 min on days 
–9 to –6 (total dose 120 mg/m2) followed by i.v. BU at 3.45 mg/kg infused over 2 h 
from days –5 to –2 (total dose 13.8 mg/kg i.v.). The regimen was adapted according 
 
 VI.4
to a phase II study in which CY was replaced by fludarabine combined with a 
targeted dose of oral BU.11 In a pilot study, we could show that intra- and interpatient 
variability can be significantly reduced by using i.v. BU with minimal dose 
adjustments.12 
 
GVHD prophylaxis 
The prophylactic regimen consisted of a combination of tacrolimus with targeted 
MMF. Tacrolimus with MMF had been described previously to induce a higher AUC 
of MPA compared to CsA/MMF in solid organ transplant recipients.13 According to 
the current hypothesis, CsA leads to a more profound blockade of biliary secretion of 
MPAG which inhibits secondary reabsorption of the compound. According to the 
records, tacrolimus was given orally starting on day –1 at 0.03 mg/kg split into  
 
 
Table 1        Patient and transplant characteristics 
_______________________________________________________________________________________________________________________________________ 
No. of patients  29 
Age (years), range (median), 21–69 (53), 17/12 
gender (M/F) 
 
CMV status 
 Recipient+/donor+  14 
 Recipient+/donor–  3 
 Recipient–/donor+  2 
 Recipient–/donor–  10 
 
Time to transplant (months), 1–65 (14) 
range (median) 
 
Disease 
MDS    8 
  CMML  2 
  RAEB  4 
  sAML  2 
  Cytogenetics 
   Normal  2 
   Complex Aberrant  2 
   –7  1 
   –7, +8, –Y  1 
   Unknown  2 
 
AML    11 
  CR  6 
  Relapse  3 
  Primary induction failure  2 
 
  Cytogenetics 
   Normal  7 
   Complex Aberrant  2 
   11q23  1 
   del12  1 
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NHL    6 
  Relapse  4 
  PR  1 
  Primary induction failure  1 
 
Hodgkin’s lymphoma  2 
  CR  1 
  PR  1 
 
Multiple myeloma  2 
  Relapse  2 
 
HSC donor (PBSC 26, BM 3) 
  HLA-matched related  7 
  Unrelated 
   HLA-A, -B, -C, DRB1 and 13 
   DQB1 matched 
   -A, -B or -C mismatch  6 
   DRB1 or DQB1 mismatch  3 
PBSC dose 
  CD34+ cells x106/kg, median (range)  5.9 (2.5–9.9) 
  CD3+ cells x108/kg, median (range)  3.15 (1.6–6.7) 
Donor 
 Donor female/recipient male  5 
_______________________________________________________________________________________________________________________________________ 
 
Abbreviations: + = seropositive; – = seronegative; CMML = chronic myelomonocytic leukemia;  
MDS = myelodysplastic syndrome; RAEB = refractory anemia with excess of blasts. 
 
 
two doses to achieve trough blood levels of 5–10 ng/ml. We used a minimally lower 
target level for tacrolimus compared to other investigators to avoid excess toxicity 
when escalating MMF doses.14 In case of mucositis, nausea or patient preference, 
tacrolimus was administered intravenously during their stay at hospital. MMF 
(Cellcept) was started on day 0 at 1.5 g intravenously b.i.d. The dose adjustments 
were scheduled after the respective days of MPA AUC measurements and were 
calculated according to a linear model. Flat dosing of the initial MMF application was 
chosen instead of a body weight-based regimen because dose optimization was 
already expected to occur on day 4. Patients were switched to the oral formulations 
of tacrolimus and MMF before discharge. Oral MMF was dosed equivalently to the 
last targeting level and continued until day 56. If no GVHD had occurred, MMF was 
gradually decreased until day 84. Tacrolimus was gradually decreased starting on 
day 120 with the goal to be off medication around day 180. In case of acute GVHD 
≥grade II, patients received therapy with prednisolone at 2 mg/kg for 5–7 days with a 
decrease after clinical response. Steroid-refractory GVHD was either treated with 
anti-TNF-α antibodies (infliximab) or pentostatin. 
 
 
Donor selection and blood stem cell harvest 
Related or unrelated donors were selected on the basis of compatibility for HLA-A,  
-B, -C, DRB1 and DQB1 by intermediate or high-resolution DNA typing. Mismatch for 
a single HLA-A, -B, -C, DRB1 and DQB1 allele was allowed within the same broad 
serotype (that is, A*0101 vs 0102) or within a cross-reactive group (that is, A*0101 vs 
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0301). Data are summarized in Table 1. Female donors had to be chosen in five 
cases. 
   Injection of the donor with G-CSF and apheresis were performed according to the 
policy of the collection center. PBSCs were stored overnight at 4 1C when necessary. 
A target dose of 44.0_106 CD34þ cells per kg was requested. The dose of infused 
CD34þ and CD3þ cells is shown in Table 1. Blood stem cells were infused on day 0 
without further manipulation. 
 
 
Pharmacokinetic studies ofMPA, MPAG and MPA targeting 
On days 3, 7 and 11 after transplantation, AUC measurements of MPA were 
performed. Blood samples were collected at 0, 0.5, 2, 3, 4, 7, 9 and 12 h after start of 
the 2 h MMF infusion. Details of the chemical and pharmacokinetic analyses for MPA 
and MPAG have been described.15 Briefly, after organic extraction, the compounds 
were separated on a Spherisorb ODS-2 column (Waters, Eschborn, Germany) 
followed by post-column derivatization. Chromatograms were detected with 
Fluorescence Spectroscopy. The amounts of MPA and the MPAG were evaluated 
from peak areas. 
   The modification of the actual MMF dose was planned to be adjusted 24 h after the 
preceding pharmacokinetic assessment. If the AUC achieved was less than 35 or 
more than 60 µg/ml/h, subsequent doses were adjusted to a proportional 
approximation: old dose x target MPA-AUC/ measured MPA-AUC. This target level 
was adapted from a consensus recommendation for therapeutic drug monitoring of 
MMF after solid organ transplantation.16 The calculated dose was rounded to 250mg 
intervals. The schedule of drug dosing and AUC measurements is summarized in 
Figure 1. 
 
 
Regimen-related toxicity 
Regimen-related toxicity was scored using the Common Toxicity Criteria version 3 of 
the National Cancer Institute (http://ctep.cancer.gov/reporting/ctc.html). During the 
first 100 days after transplantation, we evaluated mucositis and neurological, 
gastrointestinal, hepatic, pulmonary and hematological toxicity. Any positive blood 
culture for pathogenic bacteria or candida species was documented as bacteremia or 
candidemia, respectively. Bacterial and yeast organ site infection as well as invasive 
mold infection required positive culture results from a biopsy taken at a sterile site or 
histologic evidence. The duration of hospitalization was recorded. 
 
 
Engraftment and chimerism 
Chimerism of PBLs was performed twice per week from engraftment until day 28 and 
weekly thereafter until day 100. Cellular DNA was amplified for at least three short 
tandem repeat loci. The amplified fragments were examined to identify informative 
host or donor markers, and the respective signals were quantified, as previously 
described.17 
 
 
Supportive care 
Tests for CMV pp65 antigen or PCR for CMV DNA were performed weekly. In case 
of a positive test result, preemptive therapy with ganciclovir 5 mg/kg q12 to 24 h was 
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initiated and administered until PCR results became negative. Infectious disease 
prophylaxis strategies were employed during this study, including the use of systemic 
antibacterial antibiotics and fluconazole. All CMV seronegative patients received 
either screened or filtered blood products. Acyclovir was given for herpes simplex 
virus and VZV prophylaxis to seropositive patients for 1 month and 1 year, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1   Study design. Schedule of pharmacokinetic monitoring and 
                  mycophenolic acid-area under the concentration-based 
                      adaptation of mycophenolate mofetil doses in the early  
                      post transplantation period. 
 
 
Causes of death 
Deaths after relapse were categorized as due to malignancy irrespective of the 
proximate cause. Deaths without relapse were categorized as non-relapse deaths. 
Infection was listed as the cause of death when a bacterial, viral or fungal infection 
was the proximate cause of death in patients who had not relapsed. GVHD was 
indicated as a contributor to death if active GVHD was present at the time of death 
from any cause in the absence of leukemia relapse. 
 
 
Statistical analysis 
The primary end point of the study was to determine the feasibility and toxicity of 
targeting MMF doses according to the plasma levels. Secondary end points included 
the incidence of donor stem cell engraftment, the incidence and severity of acute 
GVHD and the risk of persistent or recurrent disease. Acute GVHD was categorized 
clinically as ≥grade II, or grade III or IV according to the Glucksberg grading 
system.18 Estimates of survival and disease-free survival were obtained by the 
method of Kaplan and Meier, where patients were censored at last follow-up if still 
alive. The incidences of relapse, non-relapse mortality and acute GVHD were 
calculated using cumulative incidence estimates.19 Non-relapse mortality and relapse 
were treated as competing risks. 
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Results 
 
MPA pharmacokinetics and MMF doses area under the concentration and Cmax of 
MPA after 3 days of 2 x 1500mg i.v. are summarized in Figure 2. Overall, 15 out of 
29 patients evaluable (52%) achieved the target AUC with the initially prescribed 
dose. All other patients (n=14) required a dose increase on day 4 of the study 
records. After the second MPA measurement, one-third of the patients (n=10) still 
required a further dose increase, whereas a dose reduction was considered in one 
patient only. In the majority of patients (n=20, 69%) MMF doses could be adjusted to 
achieve the target AUC on day 11 after transplantation. Dose reduction was only 
performed in two cases on day 12, whereas dose increases were still required in 
seven patients (23%). 
   The maximum daily dose of MMF administered so far was 5 g b.i.d. 
   After first targeting on day 3, daily doses were increased to 3.5 g (n=3) and 4 g 
(n=11), and on day 7, they were increased to 3.5 g (n=1), 4 g (n=6), 4.5 g (n=3) and 
5 g (n=1). As expected, we observed a significant correlation between Cmax and AUC 
for MPA in 28 patients evaluable at all points in time (P<0.0001, R=0.48; Figure 3). 
The Cmax levels after about 2 h corresponding to the target AUC ranged between 16 
and 25 µg/ml. 
   The median AUC12 for MPA on days 3, 7 and 11 was 35.1, 41.3 and 43.1 µg/ml/h, 
respectively. For MPAG the corresponding values were 471, 551 and 652 µg/ml/h. 
No association between higher exposure toward MPAG and specific toxicities could 
be found. 
 
MPA AUC12h and Cmax 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  Mycophenolic acid-area under the concentration (AUC) as measured on days 3, 7 and 11 after transplantation. The graph  
                  shows the AUC and Cmax values measured for all patients on the respective targeting days. The boxes depict 25%, the  
                  median and 75% for each sample. Whiskers mark maximum and minimum values. The dotted lines represent the range of  
                  the target AUC. 
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Linear regression of Cmax and AUC 12h (28 pts) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3    Correlation of area under the concentration (AUC) and Cmax.  
                   A linear correlation between AUC and Cmax of mycophenolic  
                   acid could be demonstrated. R=0.48, P<0.0001. Complete  
                   pharmacokinetic data were available for 28 patients on days  
                   3, 7 and 11, respectively. 
 
 
Engraftment and chimerism 
Twenty-eight evaluable patients achieved sustained engraftment. Neutrophil counts 
of ≥0.5 x 109/l on three consecutive laboratory tests were reached after a median of 
13 (range, 10–30) days. Platelet counts of ≥50 x 109/l were reached after a median of 
13.5 (range 8–132) days. In one patient with myelodysplastic syndrome who died on 
day 30, engraftment had not occurred until death, although donor chimerism was 
complete on day 20. Chimerism tests showed timely engraftment donor 
hematopoiesis in all patients assayed. At 1 year, overall chimerism ranged between 
95 and 100% (median 99.5%). 
 
 
Regimen-related toxicity 
Non-fatal and fatal toxicities associated with therapy are specified and graded in 
Table 2. Non-fatal toxicities included: mucositis, colitis and sinusoidal obstruction 
syndrome/veno-occlusive disease of the liver. No infection with herpes simplex virus 
or VZV occurred during the first 100 days after transplantation. Out of 19 cases in 
which either patient and/or donor had been CMV seropositive, PCR-positivity 
requiring pre-emptive antiviral therapy was documented in 13 patients. 
 
 
GVHD 
Grades II to IV acute GVHD occurred in 16 (57%) out of 28 evaluable patients with 
onset between 5 and 61 (median 18) days (Figure 4). Grade III acute GVHD was 
observed in four (14%) patients, and four patients (14%) had grade IV acute GVHD. 
Two cases of hyperacute skin GVHD occurring before neutrophil engraftment was 
achieved. There was no detectable difference in the incidence and severity of acute 
GVHD between patients receiving a graft from related compared to unrelated donors. 
Twenty-four patients (83%) survived beyond day 100, and eight (33%) developed 
chronic GVHD that was extensive in five (19%) and limited in three patients. 
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Table 2           Toxicity and causes of death 
_______________________________________________________________________________________________________________________________________ 
Engraftment Days 
 Neutrophils > 0.5 x 109/l, median 13 (10–30) 
 (range) 
 Platelets > 50 x 109/l, median (range) 13.5 (8–132) 
 
Toxicity, non-fatal, days 0–100 No. of patients 
 Mucositis 
  Grade 0  1 
  Grade 1  14 
  Grade 2  9 
  Grade 3  5 
  Veno-occlusive disease 1 
  Colitis 
  Grade 0  5 
  Grade 1  13 
  Grade 2  9 
  Grade 3 2 
CMV DNAemia  (Out of 19 seropositive 
   pairs) 13 
 
Fatal toxicity and causes of death 
  Relapse or progression  5 
  Pneumonia  1 
  Sepsis  1 
  GVHD  5 
  Idiopathic pneumonitis  2 
_______________________________________________________________________________________________________________________________________ 
 
Survival 
The actuarial probability of overall survival and disease-free survival are 46 and 38%, 
respectively (overall survival is shown in Figure 5a). The Karnofsky performance 
score of the 15 surviving patients ranged between 60 and 100% (median 90%) by the 
time of last follow-up. There were nine deaths in patients who had not relapsed. 
Causes of death were bacterial sepsis (n=1), pneumonia (n=1), idiopathic pneumonia 
syndrome (n=2) and GVHD (n=5). The cumulative incidence of death without relapse 
was 12% at day 100 and 33% at 12 months (Figure 5b). 
 
 
Relapse 
Malignancy persisted or recurred in six cases. One patient is alive after post 
transplant relapse and five died. The cumulative incidence of relapse was 19% 
(Figure 5b). 
 
 
Discussion 
 
Mycophenolate mofetil has been successfully introduced into the field of allo-HSCT. 
Although not officially licensed, many investigators have used the compound to treat 
acute and chronic GVHD.20,21 In addition, MMF was shown to be synergistic with 
CYA in inducing a stable mixed chimerism after nonmyeloablative conditioning in a 
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large animal model and in subsequent clinical studies.22,23 Studies on the use of MMF 
as part of GVHD prophylaxis have been limited in size and mostly inconclusive, as 
most investigators reported insufficient plasma levels of the active metabolite MPA.3–
5,8,24,25 Most of these studies revealed a favorable toxicity profile of combinations of 
MMF with calcineurin inhibitors compared to regimens incorporating MTX. 
Encouraging results were reported by Nash et al.,7 who demonstrated that the rate of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4    Incidence of acute GVHD. The cumulative incidence of  
                  acute GVHD grades II–IV and grades III–IV is depicted. 
 
GVHD after transplantation from matched-sibling donors could be significantly 
reduced by using higher MMF doses of up to 60 mg/kg daily. The optimum dose in 
this particular trial was 45 mg/kg, as higher doses induced toxicities without further 
reducing the risk of GVHD in recipients of grafts from matched siblings. In a study on 
the pharmacokinetics of MMF within the context of nonmyeloablative conditioning, 
application of MMF every 8 h was associated with a significantly higher MPA 
exposition and trough blood levels, which led to a decreased incidence of mixed T-
cell chimerism and graft failure.26 Unfortunately, the more profound state of 
immunosuppression led to an increased rate of CMV infections. A negative 
correlation between the rates of graft failure and GVHD and 6 h unbound MPA AUC 
has been described in a retrospective study providing further arguments for 
therapeutic drug monitoring.27 Only recently, our results concerning shortened half-
life and decreased MPA exposure in recipients of HSCTs have been confirmed by 
other investigators.28 
   Tacrolimus combined with MMF has already been explored as GVHD prophylaxis 
in two trials after nonmyeloablative conditioning and in children receiving standard 
intensity regimens. Both groups concluded that the combination was effective and 
safe.29,30 Retrospective comparisons revealed that the rate of acute GVHD was at 
least comparable to standard CYA/MTX. 
   Therapeutic drug monitoring of MMF using simplified sampling strategies have 
been advocated after solid organ transplantation.31 With this approach, most 
investigators 
hope to minimize the broad interpatient variability of MPA exposure especially in 
critically ill patients. The current investigation suggests that targeting of individual 
MMF doses according to the pharmacokinetic values is feasible in the early phase 
after allo-HSCT and allows for a controlled supply of MMF as a potentially efficient 
compound. Although significantly higher doses than previously reported were 
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required to achieve the target AUC, no significant toxicity was specifically associated 
with the use of MMF. The most critical issue seems to be the early phase after 
transplantation during which levels tended to decrease in previous studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5    Survival, TRM and relapse. Plot A shows the Kaplan–Meier estimate for overall survival (a). Cumulative incidences for  
                     treatmentrelated mortality and relapse (b) are provided in a competing risk model. 
 
This was in part compensated by the dose adaptation on day 4. But still, many 
patients achieved the targeted AUC level as late as day 11 after transplantation. This 
would argue for an intensified and more frequent pharmacokinetic targeting within the 
first 8–10 days, which is virtually impossible when 12 h AUC have to be measured 
and calculated. Therefore, it was encouraging to see that AUC and Cmax levels had a 
promising coefficient of correlation which would allow to minimize the daily 
measurements by just determining Cmax 2–3 h after starting the infusion and 
calculating the next dose to achieve levels between 16 and 30 µg/ml. This would 
allow for an intensification of the targeting regimen to achieve effective drug levels in 
the early phase after transplantation when GVHD effector cells are expanded. 
   One argument against MMF targeting could be the fact that the response to MMF is 
more correlated with the subtype of inosine monophosphate dehydrogenase 
isoenzyme of a certain cell type than with intracellular drug levels. In certain patients 
(10–15% of Caucasians), even AUC is probably not correlated with the 
immunosuppressive effects of MPA. It has to be discussed whether screening for 
inosine monophosphate dehydrogenase activity during MMF administration could be 
a future strategy to retain more reliable information on the optimum individual target 
drug level.32,33 
   The rate of acute GVHD in this series did not differ significantly from experiences 
with combinations of CYA or tacrolimus with MTX. Nevertheless, grade III–IV acute 
GVHD was observed in some cases. This fact may in part be attributed to the less 
consistent control of MPA plasma levels after patients had been switched to oral 
MMF and discharged to the outpatient department between days 14 and 21 after 
transplantation. In future trials, efforts will have to focus on optimum dosing of MMF 
from discharge until days 60–100. Probably, dosing every 8 h, and MPA 
measurements 2 h after the first morning dose can be helpful in this context. Our 
pharmacokinetic results do suggest that AUC targeting can be approximated by Cmax 
measurements, thereby making the overall approach more feasible. The current 
approach using 12 h kinetics is probably not feasible on a routine basis. New 
formulations of MMF might be of additional help in recipients of allo- HSCT to achieve 
higher plasma levels of MPA in the outpatient setting.34 
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   In conclusion, our study shows that individual MMF targeting according to AUC of 
MPA is feasible and effective in the early phase after allo-HSCT. The doses required 
to achieve the target AUC were not associated with dose-limiting toxicities. Given the 
high proportion of unrelated transplants, the rate of acute and chronic GVHD as well 
as the rate of overall survival seem to be acceptable. A modified daily dosing 
schedule in the outpatient setting seems to be warranted in future trials. Replacing 
AUC by Cmax targeting would lead to a more practical strategy probably also useful in 
the outpatient setting. 
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VII 
 
Abkürzungsverzeichnis 
 
 
 
allo-(H)SCT   allogenic (hematopoietic) stem cell transplantation 
AML    acute myeloic leukemia 
AUC    area under the concentration 
b.i.d.    twice a day 
BU    busulfan 
c    concentrate 
C2h           concentration at 2 h postdose 
Cmax     maximum concentration 
CMV    cytomegalovirus 
CR    complete remission 
CsA     cyclosporin A 
CY    cyclophosphamide 
dGTP    deoxyguanosine triphosphate 
DNA     deoxyribonucleic acid 
G-CCF   granulocyte colony-stimulating factor 
GvHD    graft versus host disease 
h    hour  
HLA    human leukocyte antigen 
i.v.    intravenous 
kg    kilogram  
µg    microgram 
M/F    male / female 
m2    square meter 
mg    milligram 
ml    milliliter 
MMF     mycophenolate mofetil 
MPA      mycophenolic acid 
MPAG   mycophenolic acid glucuronide 
MTX    methotrexate 
ng    nanogram 
NHL    non-Hodgkin's lymphoma 
PBSC    peripheral blood stem cells 
PCR    polymerase chain reaction 
PR    partial remission 
TRM    treatmentrelated mortality 
vs    versus 
VZV    varicella-zoster virus 
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Nach der Einarbeitung durch Herrn Dr. med. Jens Freiberg – Richter und Frau Petra 
Lorenz habe ich, Ingmar Uwe Häntzschel, das pharmakokinetische Targeting von 
Mycophenolat – mofetil nach allogener Stammzelltransplantation therapiebegleitend 
und unter Rücksprache mit Herrn Dr. med. Jens Freiberg – Richter selbstständig 
durchgeführt. 
 
 
Einbegriffen sind insbesondere die Messungen der MPA - Plasmaspiegel. 
Die Ergebnisse habe ich Herrn Dr. med. Jens Freiberg – Richter übermittelt und mit 
ihm gemeinsam die Dosis für die weitere Therapie festgelegt.  
Bei der Abnahme der Proben unterstützte mich Frau Annett Haake. 
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Daten gesammelt. Hierbei erfolgte einerseits die Erfassung des Ausmaßes der 
GvHD, eingeteilt nach dem Vorschlag der Seattle – Arbeitsgruppe, andererseits eine 
Toxizitätsanalyse nach den international gebräuchlichen CTC – Kriterien. 
 
 
Nach entsprechend statistischer Auswertung habe ich die gewonnenen Ergebnisse 
Herrn Prof. Dr. med. Martin Bornhäuser zur Diskussion vorgelegt. 
 
 
Anschließend habe ich diese Ergebnisse zu einem Manuskript zusammengefasst. 
Änderungen am Text wurden nachfolgend in Absprache mit Herrn Prof. Dr. med. 
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Thesen 
 
 
 
1. Mycophenolat-Mofetil (MMF) ist auf dem Gebiet der allogenen Stammzelltrans-
plantation (HSZT) erfolgreich eingeführt worden.  
 
2. Mycophenylsäure (MPA) hemmt die Inosinmonophosphat-Dehydrogenase und 
führt hierüber zur selektiven Hemmung der Proliferation von T- und B-Zellen. 
 
3. Die Wirksamkeit einer dosisadaptierten Gabe von MMF bezüglich der Prophylaxe 
einer akuten Graft – versus Host Disease (aGvHD) ist vergleichbar mit der kon-
ventionellen aGvHD - Prophylaxe bestehend aus Methotrexat (MTX) in Kombi-
nationen mit Cyclosporin A oder Tacrolimus. 
 
4. Neben interindividuellen Unterschieden im Metabolismus von MPA besteht bei 
Transplantationsempfängern einer HSZT eine verkürzte Halbwertszeit von MPA 
gegenüber Patienten ohne vorherige hochdosierte Konditionierung.  
 
5. Durch Dosisanpassung von MMF nach MPA-Spiegelbestimmung mittels Messung 
(en) der Area Under the Concentration (AUC) können entsprechend effektive 
MPA-Spiegel aufgebaut werden. 
 
6. Um den Sollwert der AUC von 35–60 µg/ml/h zu erreichen, kann eine Dosis-
erhöhung von MMF bis zu  5000 mg /d i.v. b.i.d. vorgenommen werden ohne 
signifikante Erhöhung der MMF - bezogenen Toxizität. 
 
7. Die MPA – AUC korreliert eng mit der maximalen Konzentration des MPA-
Spiegels (= Cmax).  
 
8. Entsprechend dem Sollwert der AUC von 35–60 µg/ml/h liegt der Sollwert der 
Cmax- Spiegel, gemessen 2-3 h nach Infusionsbeginn (C2h), zwischen 16 und 25 
µg/ml.  
 
9. Durch Bestimmung des Cmax-Wertes 2-3 h nach dem Beginn der Infusion kann 
die Anzahl der zur Dosisfindung benötigten Messungen reduziert werden. 
 
10. Eine vereinfachte MMF-Dosisfindungsstrategie, die auf Cmax oder C2h-Spiegel von 
MPA basiert  ist ein vielversprechender Therapieansatz.  
 
11. Kurze Dosierungsintervalle in den ersten 10 Tagen nach HSZT ermöglichen eine 
effizientere Dosisanpassung bei potentiell höchstem Risiko eines Abfallens des 
MPA-Spiegels nach hochdosierter Konditionierung. 
